Sugi Predict

Sugi Predict / Compounds / SCHEMBL9935388

SCHEMBL9935388

SCHEMBL9935388

CON(C)C(=O)c1ncc(Br)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.40
▸ MEN1 O00255 5/20 0.40
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ PLAU P00749 1/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ LMNA P02545 4/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ TSHR P16473 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ PKM P14618 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18988905 0.84 MAPT (0.38) KMT2AMEN1ALDH1A1MAPTSLC6A3
SCHEMBL29882423 0.84 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1MAPTPLAU
SCHEMBL18921616 0.84 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1MAPTPLAU
SCHEMBL21591714 0.83 KMT2A (0.36) KMT2AMEN1ALDH1A1MAPTTDP1
SCHEMBL23706004 0.82 KMT2A (0.39) KMT2AMEN1TDP1OPRK1
SCHEMBL2943288 0.82 MLYCD (0.36) KMT2AMEN1TDP1PIK3CAMTOR
SCHEMBL21591673 0.79 KMT2A (0.39) KMT2AMEN1TDP1POLBOPRK1
SCHEMBL1599853 0.79 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1SLC6A3TDP1
SCHEMBL29915138 0.79 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1SLC6A3TDP1
SCHEMBL13388611 0.79 GRM5 (0.41) KMT2AMEN1ALDH1A1MAPTPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190865-A1 T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-13 — — US disclosed
WO-2024081653-A2 METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES ACUREX BIOSCIENCES CORPORATION (US) 2024-04-18 — — WO disclosed
EP-4301759-A2 T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF The Board of Trustees of the Leland Stanford Junior University (US) 2024-01-10 — — EP disclosed
CN-116917289-A T-type calcium channel antagonists and uses thereof 小利兰·斯坦福大学董事会 2023-10-20 — — CN disclosed
WO-2022216386-A9 T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-12-01 — — WO disclosed
WO-2022216386-A2 T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-10-13 — — WO disclosed
EP-3549933-B1 HETEROCYCLIC COMPOUND, AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL CO (JP) 2022-02-16 — — EP disclosed
EP-3549933-A1 HETEROCYCLIC COMPOUND, AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME Sumitomo Chemical Company, Limited (JP) 2019-10-09 — — EP disclosed
EP-3495360-A1 HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES Grünenthal GmbH (DE) 2019-06-12 — — EP disclosed
WO-2018101424-A1 HETEROCYCLIC COMPOUND, AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME 住友化学株式会社 2018-06-07 — — WO disclosed
US-9302996-B2 Continuous arycyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-04-05 — — US disclosed
US-9302996-B2 Continuous arycyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-04-05 — — US disclosed
WO-2015158427-A1 HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES Grünenthal GmbH (DE) 2015-10-22 — — WO disclosed
US-20150291572-A1 HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES Grünenthal GmbH (DE) 2015-10-15 — — US disclosed
EP-2651915-A1 CONTINUOUS ARYCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2013-10-23 — — EP disclosed
US-20130261128-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-10-03 — — US disclosed
US-20130261128-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-10-03 — — US disclosed
US-20130261128-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-10-03 — — US disclosed
WO-2012081736-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-21 — — WO disclosed
WO-2012081736-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190865-A1 T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF CACNA1G, CACNA1H, CACNB2 KMT2A 3166/4885MEN1 1661/4885ALDH1A1 4605/4885
US-20150291572-A1 HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES TRPV1, CACNA1B, CACNA1C KMT2A 3739/4885MEN1 4047/4885ALDH1A1 2565/4885
US-20130261128-A1 CONTINUOUS ARYCYCLIC COMPOUND DGAT1, DGAT2, SOAT1 KMT2A 582/4885MEN1 3723/4885ALDH1A1 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.